Pharma’s sustainability problem was never a factory problem. Four-fifths of the footprint sits in the supply chain and in the molecule itself. What changed in the last twelve months, who is now asking for what, and what a small developer should do about it.
Read moreWhat 185 formulation professionals expect the excipient of 2030 to look like, and why it answers the question an IPEC-Europe panel put at CPHI Milan.
Read moreThe one per cent gets quoted. The variance around it is larger, less discussed, and a harder problem than the mean.
Read moreWhy an oral peptide delivers about one per cent of its dose – and what the tablet has to carry to manage even that.
Read more
Five NSAIDs from one pharmacological class have five different transdermal fates. No molecular descriptor predicts which, and neither does the flux calculation that comes closest.
Read more
Ozempic is a pill now, but oral bioavailability wasn’t solved. How Novo Nordisk and Eli Lilly reached comparable results by two opposite routes.
Read moreA 2020 mouse study hit an oral bioavailability no approved oral peptide drug has matched in a human. Why lipid-based delivery — […]
Read more
Eli Lilly took an undisclosed equity stake in Oura, not a company. What that says about personalised medicine and the future of drug delivery.
Read moreWhy a red syrup tastes sweeter before it’s swallowed: the psychology of colour, taste and liquid medicine, from Ibumix.
Read moreThe Second Battle, Opened From the Inside Octreotide, acromegaly and the tight-junction trick that takes on the gut wall directly Rybelsus proved […]
Read more